G
Guillermo Garcia-Manero
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1611
Citations - 52621
Guillermo Garcia-Manero is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Myelodysplastic syndromes. The author has an hindex of 108, co-authored 1411 publications receiving 43103 citations. Previous affiliations of Guillermo Garcia-Manero include Sapporo Medical University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
24-Month Analysis of the Impact of Chelation on Clinical Outcomes in a 600 Patient Registry of Lower-Risk MDS Patients
Roger M. Lyons,Billie J. Marek,Surabhi Sharma,Carole Paley,Jason Esposito,Lawrence Garbo,Nicholas DiBella,Guillermo Garcia-Manero +7 more
TL;DR: Use of chelation was associated with lower AML transformation, fewer cardiac events, and better OS in transfusion-dependent MDS patients, and differences between non-chelated and chelated patients are reported.
Journal ArticleDOI
Clinical Significance of Deeper Molecular Responses with Four Modalities of Tyrosine Kinase Inhibitors As Frontline Therapy for Chronic Myeloid Leukemia
Lorenzo Falchi,Hagop M. Kantarjian,Alfonso Quintás-Cardama,Susan O'Brien,Elias Jabbour,Farhad Ravandi,Gautam Borthakur,Guillermo Garcia-Manero,Srdan Verstovsek,Jan A. Burger,Rajyalakshmi Luthra,Jorge E. Cortes +11 more
TL;DR: It is suggested that deeper molecular responses (MMR and beyond) are associated with clinical benefit, with a particularly good outcome for those achieving undetectable transcript levels.
Journal ArticleDOI
CC-486 (Oral Azacitidine) Monotherapy in Patients with Acute Myeloid Leukemia (AML)
Michael R. Savona,Steven D. Gore,Kathryn S. Kolibaba,Stacey M. Ukrainskyj,Keshava Kumar,Qian Dong,Joel Hetzer,Barry S. Skikne,Guillermo Garcia-Manero +8 more
TL;DR: Evaluate the safety and efficacy of CC-486 administered in extended dosing schedules (14 days or 21 days per 28-day cycle) in patients with AML and found generally comparable responses and response rates across the 4 dosing regimens.
Journal ArticleDOI
CC-486 (Oral Azacitidine) in Patients with Hematological Malignancies Who Had Received Prior Treatment with Injectable Hypomethylating Agents (HMAs): Results from Phase 1/2 CC-486 Studies
Guillermo Garcia-Manero,Michael R. Savona,Michael R. Savona,Steven D. Gore,Bart L. Scott,Christopher R. Cogle,Thomas E. Boyd,Paul Conkling,Joel Hetzer,Qian Dong,Keshava Kumar,Stacey M. Ukrainskyj,Barry S. Skikne +12 more
TL;DR: Overall response rate (ORR) included complete remission (CR), partial remission (PR), CR with incomplete hematologic recovery (CRi), HI, and transfusion independence (TI) and rates of specific responses were similar between pts with MDS/CMML and pts with AML.
Journal ArticleDOI
The Commands Trial: A Phase 3 Study of the Efficacy and Safety of Luspatercept Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low-, Low-, or Intermediate-Risk MDS in Erythropoiesis Stimulating Agent-Naive Patients Who Require RBC Transfusions
Matteo G. Della Porta,Uwe Platzbecker,Valeria Santini,Guillermo Garcia-Manero,Rami S. Komrokji,Rodrigo Ito,Pierre Fenaux +6 more
TL;DR: The COMMANDS trial is a phase 3, open-label randomized study to compare the efficacy and safety of luspatercept versus epoetin alfa in anemic patients with IPSS-R defined myelodysplastic syndromes who require regular red blood cell (RBC) transfusions.